- Home
- ASTS vs JAZZ Comparison
ASTS vs JAZZ Comparison
Compare ASTS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTS
- JAZZ
- Stock Information
- Founded
- ASTS 2019
- JAZZ 2003
- Country
- ASTS United States
- JAZZ Ireland
- Employees
- ASTS N/A
- JAZZ N/A
- Industry
- ASTS Telecommunications Equipment
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- ASTS Consumer Discretionary
- JAZZ Health Care
- Exchange
- ASTS Nasdaq
- JAZZ Nasdaq
- Market Cap
- ASTS 6.3B
- JAZZ 6.7B
- IPO Year
- ASTS N/A
- JAZZ 2007
- Fundamental
- Price
- ASTS $46.16
- JAZZ $110.27
- Analyst Decision
- ASTS Buy
- JAZZ Strong Buy
- Analyst Count
- ASTS 7
- JAZZ 12
- Target Price
- ASTS $45.90
- JAZZ $183.08
- AVG Volume (30 Days)
- ASTS 15.2M
- JAZZ 651.1K
- Earning Date
- ASTS 08-13-2025
- JAZZ 07-30-2025
- Dividend Yield
- ASTS N/A
- JAZZ N/A
- EPS Growth
- ASTS N/A
- JAZZ 49.21
- EPS
- ASTS N/A
- JAZZ 7.51
- Revenue
- ASTS $4,636,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- ASTS $1,331.30
- JAZZ $6.05
- Revenue Next Year
- ASTS $370.72
- JAZZ $4.68
- P/E Ratio
- ASTS N/A
- JAZZ $14.72
- Revenue Growth
- ASTS 827.20
- JAZZ 5.76
- 52 Week Low
- ASTS $11.41
- JAZZ $95.49
- 52 Week High
- ASTS $54.05
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- ASTS 61.42
- JAZZ 52.75
- Support Level
- ASTS $42.44
- JAZZ $109.27
- Resistance Level
- ASTS $47.34
- JAZZ $112.70
- Average True Range (ATR)
- ASTS 3.68
- JAZZ 2.72
- MACD
- ASTS -0.99
- JAZZ 0.42
- Stochastic Oscillator
- ASTS 33.88
- JAZZ 67.81
About ASTS AST SpaceMobile Inc.
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.